Vascularization in primary breast carcinomas: Its prognostic significance and relationship with tumor cell dissemination

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2341-2350

  Dhakal, Hari Prasad ^a   Naume, Bjørn ^a   Synnestvedt, Marit ^a   Borgen, Elin ^a   Kaaresen, Rolf ^b   Schlichting, Ellen ^b   Wiedswang, Gro ^b   Bassarova, Assia ^a   Giercksky, Karl Erik ^a   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; CYCLOPHOSPHAMIDE; ENDOGLIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION;

EID: 42249090520     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4214     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
3. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
4. Ozbas S, Dafydd H, Purushotham AD. Bone marrow micrometastasis in breast cancer. Br J Surg 2003;90:290-301.
5. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
6. Kato T, Kameoka S, Kimura T, Nishikawa T, Kasajima T. Angiogenesis and blood vessel invasion as prognostic indicators for node-negative breast cancer. Breast Cancer Res Treat 2001;65:203-15.
7. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Tavassoli FA DP, editor. World Health Organization classification of tumours pathology and genetics. Tumours of the breast and female genital organs. Lyon (France): IARC Press; 2003. p.13-59.
8. Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol 2005;23:1623-6.
9. Wiedswang G, Borgen E, Kåresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;2:3469-78.
10. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
11. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
12. Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001;19:1468-75.
13. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrowof breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001;19:3669-74.
14. Solomayer EF, Diel IJ, Salanti G, et al. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 2001;7:4102-8.
15. Wiedswang G, Borgen E, Schirmer C, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006;118:2013-9.
16. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62.
17. Bamias A, Dimopoulos MA. Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med 2003;14:459-69.
18. McDonnell CO, Hill AD, McNamara DA, Walsh TN, Bouchier-Hayes DJ. Tumor micrometastases: the influence of angiogenesis. Eur J Surg Oncol 2000;26:105-15.
19. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-55.
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
21. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: evidence continues to grow. J Pathol 1998;184:119-22.
22. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996;2:1191-8.
23. Hansen S, Sorensen FB, Vach W, Grabau DA, Bak M, Rose C. Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology 2004;44:428-36.
24. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000;6:139-46.
25. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995;177:275-83.
26. Fox SB, Harris AL. Histological quantitation of tumor angiogenesis. APMIS 2004;112:413-30.
27. Fox SB, Leek RD, Bliss J, et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 1997;89:1044-9.
28. Benoy IH, Salgado R, Elst H, et al. Relative microvessel area of the primary tumor, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res 2005;7:R210-9.
29. Naume B, Borgen E, Kvalheim G, et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001;7:4122-9.
30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
31. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-79.
32. Hansen S, Grabau DA, Rose C, Bak M, Sorensen FB. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 1998;78:1563-73.
33. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
34. Offersen BV, Sorensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer-relevance to prognosis. Acta Oncol 2002;41:695-703.
35. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994;24:41-7.
36. Gasparini G, Toi M, Verderi P, et al. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol 1998;12:117-25.
37. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
38. Offersen BV, Borre M, Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 2003;39:881-90.
39. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-61.
40. Duff SE, Chenggang L, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential application. FASEB J 2003;17:984-92.
41. Dales JP, Garcia S, Andrac L, et al. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol 2004;24:1197-204.
42. Charpin C, Dales JP, Garcia S, et al. Tumor neoangiogenesis by CD31and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 2004;10:5815-9.
43. Zhou S, Wang GP, Liu C, Zhou M. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 2006;6:231.
44. Brandt B, Kemming D, Packeisen J, et al. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Endocr Relat Cancer 2005;12:823-37.
45. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
46. Fehm T, Becker S, Pergola-Becker G, et al. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res 2004;24:4211-6.
47. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-53.